Progress in the Development of Effective Vaccines to Prevent Selected Gram-Positive Bacterial Infections
暂无分享,去创建一个
[1] John D. Rose,et al. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. , 2010, The American journal of cardiology.
[2] J. Carapetis,et al. Group A streptococcal vaccines: facts versus fantasy , 2009, Current opinion in infectious diseases.
[3] L. Guilherme,et al. A vaccine against S. pyogenes: design and experimental immune response. , 2009, Methods.
[4] J. Carapetis,et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. , 2009, The Lancet. Infectious diseases.
[5] G. Grandi,et al. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. , 2009, The Journal of infectious diseases.
[6] R. Tanz,et al. Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] J. Carapetis,et al. emm and C-Repeat Region Molecular Typing of Beta-Hemolytic Streptococci in a Tropical Country: Implications for Vaccine Development , 2009, Journal of Clinical Microbiology.
[8] K. Jansen,et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. , 2009, Vaccine.
[9] D. Kaufman,et al. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. , 2009, Cochrane Database of Systematic Reviews.
[10] Jean C. Lee,et al. Staphylococcal vaccines and immunotherapies. , 2009, Infectious disease clinics of North America.
[11] J. Musser,et al. Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes. , 2008, The Journal of infectious diseases.
[12] W. Schaffner,et al. Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease: A Multistate, Population-Based Analysis , 2008, The Pediatric infectious disease journal.
[13] G. Yarranton,et al. Antibodies for the treatment of bacterial infections: current experience and future prospects. , 2008, Current opinion in biotechnology.
[14] M. Edwards. Group B streptococcal conjugate vaccine: A timely concept for which the time has come , 2008, Human vaccines.
[15] Jean C. Lee,et al. Vaccination and passive immunisation against Staphylococcus aureus. , 2008, International journal of antimicrobial agents.
[16] V. Nizet,et al. Recent advances in understanding the molecular basis of group B Streptococcus virulence , 2008, Expert Reviews in Molecular Medicine.
[17] C. Arrecubieta,et al. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. , 2008, The Journal of infectious diseases.
[18] J. Middleton. Staphylococcus aureus antigens and challenges in vaccine development , 2008, Expert review of vaccines.
[19] O. Schneewind,et al. Vaccine protection against Staphylococcus aureus pneumonia , 2008, The Journal of experimental medicine.
[20] R. Lynfield,et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] C. Woods,et al. Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia , 2007, Antimicrobial Agents and Chemotherapy.
[22] Phalla Ou,et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. , 2007, The New England journal of medicine.
[23] Mengyao Liu,et al. Active and Passive Immunizations with the Streptococcal Esterase Sse Protect Mice against Subcutaneous Infection with Group A Streptococci , 2007, Infection and Immunity.
[24] L. Madoff,et al. Recombinant Group B Streptococcus Beta C Protein and a Variant with the Deletion of Its Immunoglobulin A-Binding Site Are Protective Mouse Maternal Vaccines and Effective Carriers in Conjugate Vaccines , 2007, Infection and Immunity.
[25] L. Paoletti,et al. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. , 2007, Vaccine.
[26] C. Rizzo,et al. Efficacy of autovaccination therapy on post-coronary artery bypass grafting methicillin-resistant Staphylococcus aureus mediastinitis. , 2006, Interactive cardiovascular and thoracic surgery.
[27] R. Rappuoli,et al. Group B Streptococcus: global incidence and vaccine development , 2006, Nature Reviews Microbiology.
[28] O. Schneewind,et al. Vaccine assembly from surface proteins of Staphylococcus aureus , 2006, Proceedings of the National Academy of Sciences.
[29] K. Omoe,et al. Intranasal vaccination with a double mutant of staphylococcal enterotoxin C provides protection against Staphylococcus aureus infection. , 2006, Microbes and infection.
[30] A. Potter,et al. DNA-protein immunization against the GapB and GapC proteins of a mastitis isolate of Staphylococcus aureus. , 2006, Veterinary immunology and immunopathology.
[31] V. Fowler,et al. Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia , 2006, Antimicrobial Agents and Chemotherapy.
[32] I. Margarit,et al. Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. , 2006, The Journal of infectious diseases.
[33] M. S. Barbagelata,et al. Attenuation and Persistence of and Ability To Induce Protective Immunity to a Staphylococcus aureus aroA Mutant in Mice , 2006, Infection and Immunity.
[34] S. Foster,et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. , 2006, The Journal of infectious diseases.
[35] Charles Y. Tan,et al. A Novel Staphylococcus aureus Vaccine: Iron Surface Determinant B Induces Rapid Antibody Responses in Rhesus Macaques and Specific Increased Survival in a Murine S. aureus Sepsis Model , 2006, Infection and Immunity.
[36] B. Shen,et al. A novel peptide isolated from phage library to substitute a complex system for a vaccine against staphylococci infection. , 2006, Vaccine.
[37] H. Courtney,et al. Anti‐phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M‐related protein , 2006, Molecular microbiology.
[38] S. Black,et al. Prospects for active and passive immunization against Staphylococcus aureus. , 2006, The Pediatric infectious disease journal.
[39] G. Bensi,et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome , 2006, Nature Biotechnology.
[40] Fredric Carlsson,et al. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non‐opsonic epitopes , 2006, Molecular microbiology.
[41] J. Carapetis,et al. The global burden of group A streptococcal diseases. , 2005, The Lancet. Infectious diseases.
[42] A. Bisno,et al. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] J. Langley,et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] G. Bensi,et al. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[45] S. Black,et al. Prevention of Staphylococcus aureus infections: advances in vaccine development , 2005, Expert review of vaccines.
[46] Jaideep P. Sundaram,et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[47] E. Gorovits,et al. Characterization of a Humanized Monoclonal Antibody Recognizing Clumping Factor A Expressed by Staphylococcus aureus , 2005, Infection and Immunity.
[48] A. Nakane,et al. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection. , 2005, FEMS immunology and medical microbiology.
[49] H. Tettelin,et al. Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen , 2005, Science.
[50] Bart J. Currie,et al. Surface Analyses and Immune Reactivities of Major Cell Wall-Associated Proteins of Group A Streptococcus , 2005, Infection and Immunity.
[51] Kevin F. Jones,et al. Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus Vaccine , 2005, Infection and Immunity.
[52] R. Feldman,et al. Vaccination against Group B streptococcus , 2005, Expert review of vaccines.
[53] A. Fattom,et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. , 2004, Vaccine.
[54] S. Olmsted,et al. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. , 2004, Vaccine.
[55] James D. Campbell,et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. , 2004, JAMA.
[56] M. Pichichero. Group A streptococcal vaccines. , 2004, JAMA.
[57] C. Baker,et al. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. , 2004, The Journal of infectious diseases.
[58] L. Weisman. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient , 2004, Current opinion in infectious diseases.
[59] A. Potter,et al. Characterization of two proteins of Staphylococcus aureus isolated from bovine clinical mastitis with homology to glyceraldehyde-3-phosphate dehydrogenase. , 2004, Veterinary microbiology.
[60] A. Fattom,et al. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. , 2004, American heart journal.
[61] D. Kasper,et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. , 2004, The Journal of infectious diseases.
[62] M. Höök,et al. MSCRAMM--targeted vaccines and immunotherapy for staphylococcal infection. , 2004, Current opinion in drug discovery & development.
[63] A. Fattom,et al. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. , 2004, Vaccine.
[64] G. Lindahl,et al. Intranasal Immunization of Mice with Group B Streptococcal Protein Rib and Cholera Toxin B Subunit Confers Protection against Lethal Infection , 2004, Infection and Immunity.
[65] K. O'Riordan,et al. Staphylococcus aureus Capsular Polysaccharides , 2004, Clinical Microbiology Reviews.
[66] H. Courtney,et al. Serum Opacity Factor (SOF) of Streptococcus pyogenes Evokes Antibodies That Opsonize Homologous and Heterologous SOF-Positive Serotypes of Group A Streptococci , 2003, Infection and Immunity.
[67] D. Kasper,et al. Glycoconjugate vaccines to prevent group B streptococcal infections , 2003, Expert opinion on biological therapy.
[68] K. Omoe,et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. , 2003, The Journal of infectious diseases.
[69] C. Baker,et al. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. , 2003, Vaccine.
[70] D. Kasper,et al. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. , 2003, The Journal of infectious diseases.
[71] D. Santos,et al. Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach. , 2003, Vaccine.
[72] M. Davies,et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. , 2003, The Journal of infectious diseases.
[73] Dwight R. Johnson,et al. Epidemiologic Analysis of Invasive and Noninvasive Group A Streptococcal Isolates in Hong Kong , 2003, Journal of Clinical Microbiology.
[74] S. Olmsted,et al. Immunization with C5a Peptidase or Peptidase-Type III Polysaccharide Conjugate Vaccines Enhances Clearance of Group B Streptococci from Lungs of Infected Mice , 2002, Infection and Immunity.
[75] Ian T. Paulsen,et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[76] L. Madoff,et al. Vaccines to prevent neonatal GBS infection. , 2002, Seminars in neonatology : SN.
[77] S. Bavari,et al. Protection against Bacterial Superantigen Staphylococcal Enterotoxin B by Passive Vaccination , 2002, Infection and Immunity.
[78] M. Reddish,et al. Immunogenicity of a 26-Valent Group A Streptococcal Vaccine , 2002, Infection and Immunity.
[79] S. Black,et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.
[80] T. Foster,et al. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. , 2001, The Journal of infectious diseases.
[81] Y. Li,et al. Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. , 2001, Vaccine.
[82] L. Paoletti. Potency of clinical group B streptococcal conjugate vaccines. , 2001, Vaccine.
[83] S. Hamada,et al. Systemic and Mucosal Immunizations with Fibronectin-Binding Protein FBP54 Induce Protective Immune Responses against Streptococcus pyogenes Challenge in Mice , 2001, Infection and Immunity.
[84] D. Ohlendorf,et al. Toxoids of Streptococcal Pyrogenic Exotoxin A Are Protective in Rabbit Models of Streptococcal Toxic Shock Syndrome , 2000, Infection and Immunity.
[85] M. Cunningham,et al. Pathogenesis of group A streptococcal infections. , 2000, Clinical microbiology reviews.
[86] C. Chapman,et al. Identification of an Immunodominant ABC Transporter in Methicillin-Resistant Staphylococcus aureusInfections , 2000, Infection and Immunity.
[87] G. S. Chhatwal,et al. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. , 1999, The Journal of infectious diseases.
[88] A. Conde. Staphylococcus aureus infections. , 1998, The New England journal of medicine.
[89] A. Tarkowski,et al. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. , 1998, The Journal of clinical investigation.
[90] R. Rasooly,et al. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. , 1998, Science.
[91] M. Good,et al. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. , 1997, International immunology.
[92] A. Fattom,et al. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats , 1997, Infection and immunity.
[93] P. Cleary,et al. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus , 1997, Infection and immunity.
[94] D. Kasper,et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.
[95] W. Baze,et al. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines , 1996, Infection and immunity.
[96] D. Kernodle,et al. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model , 1996, Infection and immunity.
[97] J. Sarwar,et al. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge , 1996, Infection and immunity.
[98] J. C. Lee,et al. The prospects for developing a vaccine against Staphylococcus aureus. , 1996, Trends in microbiology.
[99] J. C. Lee,et al. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis , 1995, Infection and immunity.
[100] J. Musser,et al. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. , 1994, Microbial pathogenesis.
[101] G. Lindahl,et al. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections , 1993, The Journal of experimental medicine.
[102] I. Pastan,et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A , 1993, Infection and immunity.
[103] D. Kasper,et al. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein , 1992, Infection and immunity.
[104] M. Bronze,et al. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. , 1992, Journal of immunology.
[105] V. Fischetti,et al. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. , 1990, Journal of immunology.
[106] E. Beachey,et al. Protective immunity evoked by locally administered group A streptococcal vaccines in mice. , 1988, Journal of immunology.
[107] V. Fischetti,et al. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci , 1988, Infection and immunity.
[108] D. Greenberg,et al. Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits , 1987, Infection and immunity.
[109] R. H. Johnson,et al. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein , 1979, The Journal of experimental medicine.
[110] C. Adlam,et al. Effect immunization with highly purified alpha- and beta-toxins on staphylococcal mastitis in rabbits , 1977, Infection and immunity.
[111] D. Kasper,et al. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. , 1976, The New England journal of medicine.
[112] E. N. Fox,et al. Protective studies with a group A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the upper respiratory tract. , 1975, The Journal of infectious diseases.
[113] E. N. Fox,et al. Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. , 1973, The Journal of clinical investigation.
[114] R. Lancefield. Current knowledge of type-specific M antigens of group A streptococci. , 1962, Journal of immunology.
[115] H. Swift,et al. INTRAVENOUS VACCINATION WITH HEMOLYTIC STREPTOCOCCI: ITS INFLUENCE ON THE INCIDENCE OF RECURRENCE OF RHEUMATIC FEVER IN CHILDREN , 1931 .
[116] A. R. Dochez,et al. STUDIES ON THE BIOLOGY OF STREPTOCOCCUS , 1926, The Journal of experimental medicine.
[117] O. Avery,et al. STUDIES ON THE BIOLOGY OF STREPTOCOCCUS , 1919, The Journal of experimental medicine.
[118] I. Margarit,et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. , 2009, The Journal of infectious diseases.
[119] W. Benitz. Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005 , 2009 .
[120] D. Santillan,et al. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase. , 2008, American journal of obstetrics and gynecology.
[121] J. Dale. Current status of group A streptococcal vaccine development. , 2008, Advances in experimental medicine and biology.
[122] L. Weisman. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. , 2007, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[123] J. Zabriskie,et al. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. , 2006, The Journal of infectious diseases.
[124] J. Musser,et al. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. , 2004, The Journal of infectious diseases.
[125] Rino Rappuoli,et al. Reverse vaccinology. , 2000, Current opinion in microbiology.
[126] J. Dale. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. , 1999, Vaccine.
[127] J. Zabriskie,et al. Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. , 1997, Advances in experimental medicine and biology.
[128] M. Farley. Group B streptococcal infection in older patients. Spectrum of disease and management strategies. , 1995, Drugs & aging.
[129] A. Schuchat,et al. Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. , 1994, Epidemiologic reviews.
[130] D. Watson. Staphylococcal mastitis vaccine. , 1992, Vaccine.
[131] L. Poole-Warren,et al. Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. , 1991, Clinical nephrology.